Eli Lilly EBGLYSS Data Highlights Long Term AD Potential Beyond Obesity [Yahoo! Finance]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
Eli Lilly (NYSE:LLY) presented new four year data on EBGLYSS for moderate to severe atopic dermatitis at the AAD Annual Meeting. The open label extension study reports sustained skin clearance and itch relief with EBGLYSS used as monotherapy. Researchers highlighted a favorable safety profile over the full four year period. Eli Lilly, trading at $878.24, is coming off a mixed stretch, with the share price up 7.6% over the past year, an 18.7% decline year to date, and a 14.6% decline over the past month. Against this backdrop, fresh clinical data on EBGLYSS gives investors another piece of information about the company's dermatology pipeline and the durability of one of its newer therapies. For readers tracking NYSE:LLY, the four year results add detail on how EBGLYSS is being positioned in moderate to severe atopic dermatitis, particularly as a monotherapy option. As additional clinical and real world outcomes emerge, investors can watch how dermatology contributes to Lilly's
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Novo Nordisk to launch discounted Wegovy subscriptions for self-pay patients in US [Yahoo! Finance]Yahoo! Finance
- Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disordersPR Newswire
- Franklin Rising Dividends Fund Q4 2025 Commentary [Seeking Alpha]Seeking Alpha
- Eli Lilly Is Diving Deeper Into AI Drug Discovery With Expanded Insilico Partnership [Yahoo! Finance]Yahoo! Finance
- Eli Lilly's CEO Says This Could Be a Game Changer for Its Business [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 2/4/26 - Beat
LLY
Sec Filings
- 3/26/26 - Form SCHEDULE
- 3/20/26 - Form DEFA14A
- 3/20/26 - Form DEF
- LLY's page on the SEC website